Primecap Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Primecap Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-542,100	Closed	-$40.8M	–	342
2022 Q2	$40.8M	Buy	542,100 +590	+0.1%	+$26.2K	0.04%	184
2022 Q1	$14.5M	Sell	541,510 -2,500	-0.5%	-$84K	0.01%	245
2021 Q4	$25.9M	Buy	544,010 +24,380	+5%	+$1.09M	0.02%	229
2021 Q3	$34.5M	Sell	519,630 -1,930	-0.4%	-$137K	0.02%	211
2021 Q2	$40.7M	Buy	521,560 +55,320	+12%	+$4.09M	0.03%	205
2021 Q1	$44.1M	Buy	466,240 +14,900	+3%	+$1.77M	0.03%	200
2020 Q4	$55M	Buy	451,340 +9,740	+2%	+$1.07M	0.04%	182
2020 Q3	$38.6M	Sell	441,600 -13,400	-3%	-$933K	0.03%	184
2020 Q2	$29.4M	Buy	+455,000	New	+$26.2M	0.03%	188

Primecap Management's TPTX Position: Q3 2022 in Review

Primecap Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 542,100 shares — an estimated $40.8M sold.

Primecap Management first reported a position in TPTX in Q2 2020 and held it in 9 quarters. The position peaked at $55M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Primecap Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Primecap Management sold 542,100 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $40.8M.
Primecap Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
Primecap Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $55M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Primecap Management's 13F filing for Q3 2022, filed 14 Nov 2022.